Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

@article{Verstovsek2015EfficacySA,
  title={Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.},
  author={Srdan Verstovsek and Ruben A. Mesa and Jason R. Gotlib and Richard S. Levy and Vikas Gupta and John F. DiPersio and John Vincent Catalano and Michael Werner Nikolaus Deininger and Carole B. Miller and Richard T. Silver and Moshe Talpaz and Elliott F. Winton and Jimmie H. Harvey and Murat O. Arcasoy and Elizabeth O Hexner and Roger M. Lyons and Azra Raza and Kris Vaddi and William Sun and Wei Peng and Victor A Sandor and Hagop M Kantarjian},
  journal={Haematologica},
  year={2015},
  volume={100 4},
  pages={479-88}
}
In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis. This planned analysis assessed the long-term efficacy and safety of ruxolitinib at a median follow-up of 149 weeks. At data cutoff, approximately 50% of patients originally randomized to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Longterm outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I

  • S Verstovsek, AR Mesa, J Gotlib
  • Expert Rev Pharmacoecon Outcomes Res
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…